Trials / Completed
CompletedNCT02291510
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
A Randomized, Crossover Study Assessing the Pharmacokinetics of EFB0027 Versus ETB0015 and ETB0014 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Elcelyx Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study compared the pharmacokinetics (PK) and assessed the safety of delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Met DR | metformin delayed-release tablets |
| DRUG | Met XR | metformin extended-release tablets |
| DRUG | Met IR | metformin immediate-release tablets |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2014-11-14
- Last updated
- 2016-12-02
- Results posted
- 2015-09-21
Source: ClinicalTrials.gov record NCT02291510. Inclusion in this directory is not an endorsement.